文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

瑞马唑仑与安慰剂及咪达唑仑用于支气管镜中度镇静的安全性与有效性比较

Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy.
PubMed 文献 · Chest · 2018-10-04
一句话结论支气管镜中度镇静中,瑞马唑仑成功率80.6%,显著高于安慰剂4.8%和咪达唑仑32.9%,起效更快且神经精神功能恢复更优。

该研究为前瞻性、双盲、随机、多中心、平行组试验,在美国30个中心比较瑞马唑仑与安慰剂及开放标签咪达唑仑用于纤维支气管镜中度镇静的有效性与安全性。结果显示瑞马唑仑组操作成功率80.6%,显著高于安慰剂组4.8%(P<.0001),也高于咪达唑仑组32.9%。瑞马唑仑组支气管镜开始时间更早(均值6.4±5.82分钟),术后完全清醒时间更短(中位6.0分钟,95%CI 5.2-7.1),神经精神功能恢复优于安慰剂和咪达唑仑。三组安全性相当,瑞马唑仑组严重治疗中出现的不良事件发生率为5.6%,安慰剂组为6.8%。

要点

  • 瑞马唑仑组支气管镜镇静成功率80.6%,显著高于安慰剂组4.8%(P<.0001)和咪达唑仑组32.9%。
  • 瑞马唑仑组支气管镜开始时间均值6.4±5.82分钟,早于安慰剂组17.2±4.15分钟(P<.0001)和咪达唑仑组16.3±8.60分钟。
  • 瑞马唑仑组术后完全清醒时间中位6.0分钟(95%CI 5.2-7.1),短于安慰剂组13.6分钟(95%CI 8.1-24.0,P=.0001)和咪达唑仑组12.0分钟(95%CI 5.0-15.0)。
  • 瑞马唑仑组神经精神功能恢复优于安慰剂和咪达唑仑。
  • 三组安全性相当,瑞马唑仑组严重治疗中出现的不良事件发生率5.6%,安慰剂组6.8%。

适用人群与场景

  • 接受纤维支气管镜检查并需要中度镇静的患者,来自美国30个中心的前瞻性随机双盲试验人群。

研究设计与关键结果

  • 研究设计为前瞻性、双盲、随机、多中心、平行组试验,在美国30个中心开展,比较瑞马唑仑与安慰剂及开放标签咪达唑仑用于纤维支气管镜中度镇静的有效性与安全性。
  • 镇静成功率:瑞马唑仑组80.6%,安慰剂组4.8%(P<.0001),咪达唑仑组32.9%。
  • 支气管镜开始时间(均值):瑞马唑仑组6.4±5.82分钟,安慰剂组17.2±4.15分钟(P<.0001),咪达唑仑组16.3±8.60分钟。
  • 术后完全清醒时间(中位):瑞马唑仑组6.0分钟(95%CI 5.2-7.1),安慰剂组13.6分钟(95%CI 8.1-24.0,P=.0001),咪达唑仑组12.0分钟(95%CI 5.0-15.0)。
  • 瑞马唑仑组神经精神功能恢复优于安慰剂和咪达唑仑。
  • 安全性三组相当,瑞马唑仑组严重治疗中出现的不良事件发生率5.6%,安慰剂组6.8%。

证据类型、等级与局限

  • 证据类型:前瞻性、双盲、随机、多中心、平行组试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在肺科医师监督下,瑞马唑仑可用于纤维支气管镜中度镇静,作者结论认为其有效且安全。
  • 探索性分析显示,瑞马唑仑起效快于咪达唑仑,神经精神功能恢复也快于咪达唑仑。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: While the complexity of flexible bronchoscopy has increased, standard options for moderate sedation medications have not changed in three decades. There is a need to improve moderate sedation while maintaining safety. Remimazolam was developed to address shortcomings of current sedation strategies.

METHODS: A prospective, double-blind, randomized, multicenter, parallel group trial was performed at 30 US sites. The efficacy and safety of remimazolam for sedation during flexible bronchoscopy were compared with placebo and open-label midazolam.

RESULTS: The success rates were 80.6% in the remimazolam arm, 4.8% in the placebo arm (P < .0001), and 32.9% in the midazolam arm. Bronchoscopy was started sooner in the remimazolam arm (mean, 6.4 ± 5.82 min) compared with placebo (17.2 ± 4.15 min; P < .0001) and midazolam (16.3 ± 8.60 min). Time to full alertness after the end of bronchoscopy was significantly shorter in patients treated with remimazolam (median, 6.0 min; 95% CI, 5.2-7.1) compared with those treated with placebo (13.6 min; 95% CI, 8.1-24.0; P = .0001) and midazolam (12.0 min; 95% CI, 5.0-15.0). Remimazolam registered superior restoration of neuropsychiatric function compared with placebo and midazolam. Safety was comparable among all three arms, and 5.6% of the patients in the remimazolam group had serious treatment-emergent adverse events as compared with 6.8% in the placebo group.

CONCLUSIONS: Remimazolam administered under the supervision of a pulmonologist was effective and safe for moderate sedation during flexible bronchoscopy. In an exploratory analysis, it demonstrated a shorter onset of action and faster neuropsychiatric recovery than midazolam.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Pastis NJ, Yarmus LB, Schippers F, et al. Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy. Chest. 2018. PMID: 30292760. doi:10.1016/j.chest.2018.09.015

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。